Sakar Healthcare (NSE:SAKAR) Piotroski F-Score: 6 (As of Jul. 15, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAKAR Sakar Healthcare Ltd NSE:SAKAR
60 GF Score
Price ₹904.45
GF Value ₹540.00
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sakar Healthcare Piotroski F-Score?

Sakar Healthcare NSE:SAKAR +4.74% 60 Piotroski F-Score is 6 as of Jul. 15, 2026, which is at its 10-year median of 6.00. GuruFocus rates NSE:SAKAR with a GF Score™ of 60/100 and a GF Value™ of ₹540.00 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 979 Drug Manufacturers companies, Sakar Healthcare ranks better than 78.75% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sakar Healthcare has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Sakar Healthcare's Piotroski F-Score or its related term are showing as below:

NSE:SAKAR' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 6

During the past 11 years, the highest Piotroski F-Score of Sakar Healthcare was 8. The lowest was 4. And the median was 6.

Sakar Healthcare  (NSE:SAKAR) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sakar Healthcare Piotroski F-Score Related Terms


Sakar Healthcare Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Sakar Healthcare's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sakar Healthcare Piotroski F-Score Chart

Sakar Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 6.00 8.00 6.00

Sakar Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 0.00 0.00 0.00 6.00

NSE:SAKAR vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sakar Healthcare's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sakar Healthcare Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sakar Healthcare's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sakar Healthcare's Piotroski F-Score falls into.


NSE:SAKAR
60GF Score
Sakar Healthcare Ltd NSE:SAKAR
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹305 Mil.
Cash Flow from Operations was ₹493 Mil.
Revenue was ₹2,517 Mil.
Gross Profit was ₹1,285 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (4152.61 + 4810.095) / 2 = ₹4481.3525 Mil.
Total Assets at the begining of this year (Mar25) was ₹4,153 Mil.
Long-Term Debt & Capital Lease Obligation was ₹314 Mil.
Total Current Assets was ₹1,405 Mil.
Total Current Liabilities was ₹1,095 Mil.
Net Income was ₹175 Mil.

Revenue was ₹1,776 Mil.
Gross Profit was ₹953 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (3886.591 + 4152.61) / 2 = ₹4019.6005 Mil.
Total Assets at the begining of last year (Mar24) was ₹3,887 Mil.
Long-Term Debt & Capital Lease Obligation was ₹536 Mil.
Total Current Assets was ₹887 Mil.
Total Current Liabilities was ₹632 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sakar Healthcare's current Net Income (TTM) was 305. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sakar Healthcare's current Cash Flow from Operations (TTM) was 493. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=304.846/4152.61
=0.0734107

ROA (Last Year)=Net Income/Total Assets (Mar24)
=175.02/3886.591
=0.04503175

Sakar Healthcare's return on assets of this year was 0.0734107. Sakar Healthcare's return on assets of last year was 0.04503175. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sakar Healthcare's current Net Income (TTM) was 305. Sakar Healthcare's current Cash Flow from Operations (TTM) was 493. ==> 493 > 305 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=313.53/4481.3525
=0.06996325

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=535.942/4019.6005
=0.13333216

Sakar Healthcare's gearing of this year was 0.06996325. Sakar Healthcare's gearing of last year was 0.13333216. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=1404.586/1095.371
=1.28229248

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=887.272/631.861
=1.40422023

Sakar Healthcare's current ratio of this year was 1.28229248. Sakar Healthcare's current ratio of last year was 1.40422023. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sakar Healthcare's number of shares in issue this year was 22.252. Sakar Healthcare's number of shares in issue last year was 22.015. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1284.593/2517.36
=0.51029372

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=953.22/1775.847
=0.53676921

Sakar Healthcare's gross margin of this year was 0.51029372. Sakar Healthcare's gross margin of last year was 0.53676921. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=2517.36/4152.61
=0.60621152

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1775.847/3886.591
=0.45691636

Sakar Healthcare's asset turnover of this year was 0.60621152. Sakar Healthcare's asset turnover of last year was 0.45691636. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sakar Healthcare has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Sakar Healthcare (NSE:SAKAR) has a Piotroski F-Score of 6 as of Jul. 15, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sakar Healthcare and its competitors. This is near median its historical median of 6.00. Over the past decade, Sakar Healthcare's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Sakar Healthcare ranks #208 out of 979 companies in the Drug Manufacturers industry, placing it in the top 21.2%.
Is Sakar Healthcare's Piotroski F-Score too high?
Sakar Healthcare's current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Sakar Healthcare's value of 6 is 20% above this industry median. Based on the distribution chart, Sakar Healthcare ranks #208 out of 979 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sakar Healthcare has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sakar Healthcare's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sakar Healthcare ranks #208 out of 979 companies for Piotroski F-Score. This places Sakar Healthcare in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Sakar Healthcare's value of 6 is 20% above this benchmark. Historically, Sakar Healthcare's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Sakar Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sakar Healthcare's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sakar Healthcare and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sakar Healthcare's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sakar Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sakar Healthcare (NSE:SAKAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹540.00, compared to a current price of ₹904.45 — trading 67.5% above its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Drug Manufacturers industry median of 5.00. Sakar Healthcare's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Sakar Healthcare (NSE:SAKAR), the current Piotroski F-Score is 6 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sakar Healthcare (NSE:SAKAR) Overvalued in 2026?

Based on GuruFocus' analysis, Sakar Healthcare stock appears to be overvalued. The current stock price of ₹904.45 is trading 67.5% above its estimated GF Value™ of ₹540.00. GuruFocus considers Sakar Healthcare to be Significantly Overvalued.

Key valuation signals for NSE:SAKAR:

  • Piotroski F-Score: 6 (near median its 10-year median of 6.00)
  • GF Value™: ₹540.00 vs. price of ₹904.45 (67.5% above fair value)
  • GF Score™: 60/100 with 6 warning signs
  • Industry Position: 20% above the Drug Manufacturers median (#208 of 979)

No single metric tells the full story. See the NSE:SAKAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sakar Healthcare Business Description

Address 406, Silver Oaks Comm. Complex, Opposite Arun Society, Paldi, Ahmedabad, GJ, IND, 382 007
Sakar Healthcare Ltd is engaged in manufacturing Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. The company offers its products to Sri Lanka, the Philippines, Vietnam, Cambodia, Sudan, Myanmar, Mauritius, Costa Rica, Panama, El Salvador and Paraguay.
60GF Score

Get the complete analysis for NSE:SAKAR

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹904.45
Price
₹540.00
GF Value